| Obligatory | Must not donate if: a) The donor has a condition that is infected or infectious e.g. Scabies. b) History of malignancy. c) The venepuncture site is affected. d) Required application of steroid, tacrolimus (Protopic®) or pimecrolimus (Elidel®) creams over large areas for periods of more than three weeks in the last six months. e) Ever been treated with Etretinate (Tigason®). f) Less than 36 months from the last dose of acitretin (Neotigason®). g) Less than four weeks from the last does of isotretinoin (Roaccutane®) or Alitretinoin (Toctino®). h) Has any current open skin wounds or infection. |
| Discretionary | a) If occasional use of steroid, tacrolimus (Protopic®) or pimecrolimus (Elidel®) or other creams over small areas of skin and none of the above apply, accept. b) If chronic superficial fungal infection (e.g. ringworm, athlete's foot, chronic fungal nail infection or tinea) on local therapy only or has been in contact with an infected individual, accept. c) If in contact with scabies but not obviously infected, accept. d) If malignancy was a basal cell carcinoma (rodent ulcer) and treatment is completed and all wounds healed, accept. For donors with Lichen Sclerosus requiring treatment other than topical steroid therapy only, excluding Etretinate (Tigason®): e) If more than 24 months from completing treatment, have no areas of open wound or infection, have no history of associated malignancy and symptoms are controlled with or without intermittent use of topical steroid therapy only, accept. |
| See | Is there is a specific A-Z index entry for the treatment and/or condition you are concerned about? |
| See if Relevant | Acne |
| Additional Information | A donor who has been in contact with scabies but has no symptoms (e.g. itching) does not pose a risk to other donors or staff. Damaged skin can increase the risk of infection contaminating a donation. For this reason a venepuncture should not be performed through an area of affected skin. Many malignancies spread through the blood stream. It is therefore considered safer not to accept donations of blood from people who have been diagnosed with malignancy. Treated basal cell carcinoma is an exception to this as it is not spread through the blood stream. Initial treatment of Lichen Sclerosus is through specialist care with potent steroid therapies. Treatment can also be with methotrexate and retinoids such as Etretinate (Tigason®) or acitretin (Neotigason®). If taken systemically these can cause birth defects for babies exposed to them before birth. It is important to allow time for the drug to be cleared from the blood of a donor. Some drugs take longer to be cleared than others. Under normal circumstances the use of topical treatment with steroid, tacrolimus and pimecrolimus will not result in blood levels which cause suppression of the adrenal system or immune response. Side effects are more likely if there is a skin barrier defect or high doses are used over large areas for extended periods. A large area of skin is defined as >9% (Wallace Rule of Nines). 1% is equal to the area of the closed digits and palm of the donor's hand. |
| Reason for change | The additional information section has been updated to ensure consistency with other DSG references to immunosuppression. |
| Donor Information | If you wish to obtain more information regarding a personal medical issue please contact your National Help Line. |
This entry was last updated in:
WB-DSG Edition 203 Release 71